Afatinib active against NSCLC nervous program metastases By Laura Cowen.

To handle this, the experts studied 541 patients with NSCLC who received afatinib within a compassionate use program, initiated to provide access to the drug for sufferers who experienced disease progression during treatment with erlotinib or gefitinib. Of the 541 sufferers treated with afatinib at a starting dosage of 50 mg daily, 100 had mind metastases and/or leptomeningeal disease, 74 percent of whom had a confirmed EGFR mutation.Early treatment for these susceptible individuals is also possible. According to lead researcher Professor David Bunce of Brunel University in London, these total outcomes have opened fresh avenues for screening, timely intervention and detection. He explained that early intervention may possibly also prevent or delay the onset of the disease. The study is released in the journal PLoS One. Based on the Alzheimer’s Association the disease does not have any cure and the average sufferer dies within eight years of exhibiting symptoms.

Adamis submits APC-100 IND to FDA for treatment of prostate cancer Adamis Pharmaceuticals Corporation announced today that it has submitted to the FDA an Investigational New Medication software for APC-100 to treat prostate cancers .